Disease · MONDO_0005295

intermittent vascular claudication

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. intermittent vascular claudication. Diseases, record MONDO_0005295. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005295

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: intermittent vascular claudication; Open Targets
Open Targets ID: MONDO_0005295; Open Targets
Other names: Claudication, Intermittent, Intermittent Claudication; Open Targets
Disease Ontology: DOID:3669; Disease Ontology
MeSH: D007383; MeSH
Highest stage of its drugs: Approval, for 2 of its 40 drugs, from TTD; Open Targets

Drugs40

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CILOSTAZOL	CHEMBL799	Small molecule	Approval	TTD	3	2	2	Drugs and targets
PENTOXIFYLLINE	CHEMBL628	Small molecule	Approval	TTD	2	1	1	Drugs and targets
NIACIN	CHEMBL573	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
ASCORBIC ACID	CHEMBL196	Small molecule	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
LOVASTATIN	CHEMBL503	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
SILDENAFIL	CHEMBL192	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ALPROSTADIL	CHEMBL495	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BETA CAROTENE	CHEMBL1293	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CAFFEINE	CHEMBL113	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METFORMIN	CHEMBL1431	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 40

See all 40 drugs

Targets94

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CSF3R	Granulocyte colony-stimulating factor receptor	4	Granulocyte colony stimulating factor receptor agonist	Phase 2	https://conductscience.org/library/genes/1441	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	4	HMG-CoA reductase inhibitor	Phase 3	https://conductscience.org/library/genes/3156	Drugs and targets
PDE3A	3',5'-cyclic phosphodiesterase	3	3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 3 inhibitor; Phosphodiesterase 3A inhibitor	Approval	https://conductscience.org/library/genes/5139	Drugs and targets
ADORA2A	Adenosine A2 receptor	2	Adenosine A2 receptor antagonist; Adenosine receptor antagonist	Approval	https://conductscience.org/library/genes/135	Drugs and targets
ADORA2B	Adenosine A2 receptor	2	Adenosine A2 receptor antagonist; Adenosine receptor antagonist	Approval	https://conductscience.org/library/genes/136	Drugs and targets
EDNRA	Endothelin receptor, ET-A/ET-B	2	Endothelin receptor ET-A antagonist; Endothelin receptor, ET-A/ET-B antagonist	Phase 2	https://conductscience.org/library/genes/1909	Drugs and targets
PAH	Phenylalanine-4-hydroxylase	2	Phenylalanine-4-hydroxylase activator	Phase 2	https://conductscience.org/library/genes/5053	Drugs and targets
PDE3B	3',5'-cyclic phosphodiesterase	2	3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 3 inhibitor	Approval	https://conductscience.org/library/genes/5140	Drugs and targets
PDE5A	3',5'-cyclic phosphodiesterase	2	3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 5A inhibitor	Approval	https://conductscience.org/library/genes/8654	Drugs and targets
ADORA1	Adenosine receptor	1	Adenosine receptor antagonist	Phase 3	https://conductscience.org/library/genes/134	Drugs and targets

1 to 10 of 94

See all 94 targets

Trials25

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 5 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01263925	Prostaglandin E1 in Outpatients With Intermittent Claudication	Phase 3	561	2012-06-29	Stage II Peripheral Arterial Occlusive Disease, Intermittent Claudication Fontaine Stage II PAOD	ALPROSTADIL, PENTOXIFYLLINE	Its record names the disease	ClinicalTrials.gov
NCT00403494	A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease	Phase 2	190	2021-01-07	Intermittent Claudication	SAPROPTERIN DIHYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01041417	Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease	Phase 2	159	2014-12-23	Peripheral Arterial Disease	REGRAMOSTIM	Its record names the disease	ClinicalTrials.gov
NCT00153166	ARREST PAD (Peripheral Arterial Disease)	Phase 2/3	76	2014-09-30	Arterial Occlusive Disease, Intermittent Claudication, Insulin Resistance	ATORVASTATIN, PIOGLITAZONE	Its record names the disease	ClinicalTrials.gov
NCT00914316	Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities	Not applicable	29	2017-08-09	Peripheral Arterial Disease	RANOLAZINE	Its record names the disease	ClinicalTrials.gov
NCT00071266	The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC	Phase 3	870		Intermittent Claudication, Peripheral Vascular Disease	LOVASTATIN, NIACIN	Its record names the disease	ClinicalTrials.gov
NCT00783081	Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication	Phase 2	387		Intermittent Claudication	CILOSTAZOL, K-134	Its record names the disease	ClinicalTrials.gov
NCT00062556	Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication	Phase 3	366		Intermittent Claudication, Peripheral Vascular Disease	LOVASTATIN, NIACIN	Its record names the disease	ClinicalTrials.gov
NCT03861416	"Unifuzol®" in Patients With Peripheral Arterial Disease	Phase 2	360		Peripheral Arterial Disease	ARGININE	Its record names the disease	ClinicalTrials.gov
NCT00251849	PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients	Phase 3	274		Peripheral Vascular Diseases, Intermittent Claudication	RIFALAZIL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 25

See all 25 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Alprostadil vs Pentoxifylline: serious adverse events	19 of 276	17 of 285	561	NCT01263925	Trial comparisons
Sapropterin Dihydrochloride vs Placebo: deaths from any cause	1 of 97	0 of 91	188	NCT00403494	Trial comparisons
Sapropterin Dihydrochloride vs Placebo: serious adverse events	14 of 97	11 of 91	188	NCT00403494	Trial comparisons
GM-CSF vs Placebo: serious adverse events	9 of 80	9 of 79	159	NCT01041417	Trial comparisons

Papers from its trials22

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
29160765	RESULT	1	PubMed
29132880	RESULT	1	PubMed
29132879	RESULT	1	PubMed
24221922	RESULT	1	PubMed
19228706	RESULT	1	PubMed
18774340	RESULT	1	PubMed
18388038	RESULT	1	PubMed
8918275	RESULT	1	PubMed
4597226	RESULT	1	PubMed
2056896	RESULT	1	PubMed

1 to 10 of 22

See all 22 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005295

GET https://conductscience.org/api/diseases/v1/MONDO_0005295/drugs?page=2

API reference For AI assistants